The FDA overstepped its authority, argues Dr. Ben Carson and C. Boyden Gray.
For the first two years of the COVID-19 pandemic, there were few — if any — recommendations from federal public health authorities for treatments prior to hospitalization. The issue of early treatment is critical in any discipline of medicine, and no less so here. But early treatment of COVID-19 was dismissed by the medical establishment.
If there be any doubt about the vital importance of early treatment, consider the directions from Pfizer about Paxlovid. The company insists , and the FDA now parrots , the drug should be administered as soon as possible after a COVID-19 diagnosis, and at least within 5 days of symptom onset.
While existing clinical examination has demonstrated sufficient efficacy for an emergency use authorization from the FDA, the fact remains that Paxlovid has yet to receive full approval from the agency. Recently reports […]
Excerpt Sourced From: stream.org
